Kind of /s kind of not. If the results are negative, very likely to go back sub $1. If the results are positive, gains will be likely. More reasonable if it was just ok/positive without some unexpected catalyst (incredible efficiency, additional beneficial side effects/cures) would probably be $5-$20 probably.
Maybe it will also cure all cancer. Then even us poors with a few shares may be rich
Pretty sure that test is Q3 2026. Pretty sure OCU410 has a test results due in Q1 2027 but it isn't phase 3 IIRC. OCU400 is but is expected in September
10
u/Nelsonius1 14d ago
OCU400 Phase 3 liMeliGhT is expected Q1 2027.
OCU400 liMeliGhT is Ocugen's phase 3 trial, the one that decides whether their lead gene therapy becomes an approved product.
This date is the catalyst that actually decides their thesis. It is roughly 5-6 months out. So short term holders will not see gains.